Figures
- FIGURE 1
Kaplan–Meier survival curve of patients transplanted for non-cystic fibrosis bronchiectasis (solid red line) compared to lung transplant recipients for all other diseases combined (solid blue line) with 95% confidence intervals (dashed lines).
Tables
- TABLE 1
Baseline characteristics of NCFB listed and transplant recipients
Variable Listed patients Transplanted patients Age years 47 (37–55) 47 (37–56) Sex, female 431 (60) 221 (54) BMI kg·m−2 21.8 (18.9–25.2) 21.8 (18.8–25.1) FEV1 % predicted 24 (19–31) 24 (19–31) FVC % predicted 41 (33–51) 41 (33–51) Lung allocation score 34.9 (32.8–37.6) 36.9 (34.3–43.8) Waiting-list time days 337 (110–808) 254 (83–568) Waiting-list time post-LAS days (n=202) 170 (54–450) 119 (36–301) Data expressed as median (interquartile range) or n (%). NCFB: non-cystic fibrosis bronchiectasis; BMI: body mass index; FEV1: forced expiratory volume in 1 s; FVC: forced vital capacity; LAS: lung allocation score.
- TABLE 2
Overall number depicting the type of transplant and the outcomes following lung transplantation in the cohort of 407 non-cystic fibrosis bronchiectasis patients
Outcome n (%) Alive 114 (28) Dead 263 (65) Missing data 16 (4) Retransplanted 14 (3) - TABLE 3
Summary of survival for lung transplant recipients in the post-LAS period for NCFB compared to an age- and sex-matched cohort
Group Median (IQR) years 1-year survival % 5-year survival % 10-year survival % NCFB 6.0 (2.3–11.9) 87 53 16 Matched cohort 5.5 (2.3–13.2) 84 55 28 LAS: lung allocation score; NCFB: non-cystic fibrosis bronchiectasis; IQR: interquartile range.
- TABLE 4
Aetiology of death for non-cystic fibrosis bronchiectasis lung transplantation recipients
Aetiology of death n (%) Graft failure 64 (24) Infection 59 (23) Respiratory failure 49 (19) Unknown 39 (15) Multiple organ failure 14 (5) Cardiovascular 12 (5) Malignancy 11 (4) Cerebrovascular 6 (2) Haemorrhage 4 (2) Renal failure 4 (2) Suicide 1 (0.4)
